再発性/転移性頭頸部癌患者における標準治療薬（SOC）へのアミバンタマブ追加投与とSOC単独投与との比較試験

基本情報

NCT ID

NCT07276399

ステータス

募集中

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

500

治験依頼者名

Janssen Research & Development, LLC

概要

The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refractory/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). HNSCC is a type of cancer that develops in the head and neck regions, including the outer tissue layer of the mouth and throat. This study will focus on participants with HNSCC who are treatment-naive (have not received prior treatment) in the R/M setting.

対象疾患

介入

依頼者（Sponsor）

実施施設 (7)